Claybrook Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Claybrook Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,335	Closed	-$471K	–	256
2021 Q2	$471K	Buy	+2,335	New	+$488K	0.15%	112
2019 Q1	–	Sell	-4	Closed	-$1K	–	671
2018 Q4	$1K	Buy	+4	New	+$693	﹤0.01%	741

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Claybrook Capital's VRTX Position: Q3 2021 in Review

Claybrook Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 2,335 shares — an estimated $471K sold.

Claybrook Capital first reported a position in VRTX in Q4 2018 and held it in 2 quarters. The position peaked at $471K in Q2 2021. 933 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Claybrook Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Claybrook Capital sold 2,335 Vertex Pharmaceuticals shares in Q3 2021, an estimated $471K.
Claybrook Capital first reported a position in Vertex Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Claybrook Capital's Vertex Pharmaceuticals position peaked at $471K in Q2 2021.
933 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Claybrook Capital's 13F filing for Q3 2021, filed 15 Nov 2021.